Medicare's $50 GLP-1 Bridge: The BALANCE Model Explained

The Medicare GLP-1 Bridge is a demonstration programme run by the Centers for Medicare and Medicaid Services. Beginning 1 July 2026, eligible Medicare beneficiaries with Part D coverage can access certain GLP-1 medications at $50 for a monthly supply.

It sits within a wider CMS initiative called the BALANCE Model — Better Approaches to Lifestyle and Nutrition — which extends GLP-1 coverage across Medicaid and Medicare. Medicaid coverage under BALANCE was slated to launch as early as May 2026, with fuller Medicare Part D integration following in January 2027.

Eligibility is defined and enforced rather than aspirational. Medicare's own guidance sets out the criteria clearly.

• You must be 18 or older.
• You must be enrolled in a Medicare Part D plan, or a Medicare Advantage plan that includes prescription drug coverage.
• You must need the GLP-1 medication for weight loss and weight maintenance — this is the indication the Bridge covers.
• You must meet a BMI threshold when you start GLP-1 therapy: a BMI of 35 or higher, or a lower BMI combined with qualifying health conditions.
• A medical provider must submit a prior authorisation request on your behalf.

One detail is worth flagging because it catches people out: your BMI is assessed at the point you start therapy. If you have already lost weight through other means and now fall below the threshold, you may not qualify — even though the treatment is intended in part to help maintain that loss.

1. 1

   Confirm your Part D enrolment

   You need Part D or a Medicare Advantage plan with drug coverage. If you are on Original Medicare without Part D, enrolling is the first step and it is subject to normal enrolment periods.

2. 2

   Get your BMI and conditions documented

   Eligibility turns on a documented BMI at the start of therapy, plus qualifying conditions where your BMI is below 35. Make sure a clinical visit records both properly.

3. 3

   Have your provider submit prior authorisation

   A medical provider must submit a prior authorisation form. This is the step where most applications succeed or fail, and thorough documentation of comorbidities matters.

4. 4

   Confirm eligibility with the pharmacy

   The pharmacy receives confirmation that you are eligible for the Bridge before your doctor's approval form is processed. Both pieces need to line up.

5. 5

   Pay the $50 copay

   Once approved, eligible GLP-1 drugs are furnished at $50 for a monthly supply, outside the normal Part D payment structure.

The gap is not marginal. For an eligible Medicare beneficiary, the Bridge turns a treatment that cost several thousand dollars a year into one costing $600. That is the difference between treatment being theoretical and treatment being real for a very large number of older adults.

• It is a demonstration with an end date. Coverage under the model has been framed as running from July 2026 through the end of 2027, with the wider BALANCE integration following. Do not assume indefinite continuation.
• Only certain GLP-1 medications are eligible. The Bridge covers select drugs rather than the whole class, so your preferred product may not be included.
• Prior authorisation is required, and it can be denied. As with commercial coverage, denials are frequently overturned on appeal with better documentation.
• BMI is assessed at the start of therapy, which disadvantages people who have already lost weight and want help maintaining it.
• Food noise severity is not a criterion. As with every coverage framework, eligibility turns on BMI and comorbidities, not on how disabling your symptoms are.

Older adults have the longest histories of food noise of any group — often five or six decades of intrusive food thoughts, accumulated through generations of diet culture, and until now essentially no pharmacological option available to them under Medicare.

There is also a specific clinical argument for treating this population. Cost is the leading reason patients stop GLP-1 treatment, and food noise returns within weeks of stopping. A $50 copay is one of very few price points at which long-term treatment is genuinely sustainable on a fixed income.

The counterweight is the demonstration's end date. Building a treatment plan around coverage scheduled to expire is a real risk, and patients should discuss with their prescriber what happens if the programme is not extended — including whether a lower maintenance dose might be sustainable at manufacturer self-pay pricing.